Andes orthohantavirus (ANDV), a species of Orthohantavirus, is a major causative agent of hantavirus cardiopulmonary syndrome (HCPS) and hantavirus pulmonary syndrome (HPS) in South America. It is named for the Andes mountains of Chile and Argentina, where it was first discovered. Originating in the reservoir of rodents, Andes orthohantavirus is easily transmitted to humans who come into contact with infected rodents and/or their fecal droppings. However, infected rodents do not appear ill, so there is no readily apparent indicator to determine whether the rodent is infected or not. Additionally, Andes orthohantavirus, specifically, is the only hantavirus that can be spread by human to human contact via bodily fluids or long-term contact from one infected individual to a healthy person.
- 1 Discovery
- 2 Classification
- 3 Genome and Structure
- 4 Entry and Replication Cycle
- 5 Signs and Symptoms
- 6 Associated Diseases, Prevention, and Treatment
- 7 References
- 8 External links
Andes orthohantavirus was first identified when outbreaks of this new infection spread throughout Chile and Argentina. In 1995, it was finally characterized in Argentina on the basis of specimens from a patient who had died from HPS complications, a severe consequence of infection from Andes viruses. As an emerging virus, it is more lethal than that of some of the other hantaviruses having an mortality rates between 40% and 50% in South America. By far, it has been responsible for the most recorded cases of HPS in Argentina, Chile, and Uruguay combined and contributes to a large amount of renal failure cases. Although it can be carried by both humans and rodents, Andes orthohantavirus is most commonly found in the Oligoryzomys longicaudatus, a species of pygmy rat native to the Chile-Argentina region, and in other cases, in the Abrothrix longipilis, a long-haired grass mouse.
Andes orthohantavirus is a species of the Hantavirus, a group of enveloped, Negative-sense single-stranded RNA virus, belonging to the family Hantaviridae. The family consists of 5 genera: bunyavirus, phlebovirus, nairovirus, tospovirus, and hantavirus. All genera excluding hantavirus are air-borne viruses while the hantavirus is rodent-borne. Transmission of the hantaviruses are through aerosol exposure to rodent bodily fluids. Additionally, Hantaviruses seem to cause no detectable cytopathology in vertebrate cell cultures.
Genome and Structure
The spherical virion of the Hantavirus is typically 80-120 nm long and contains the segmented single-stranded genome. The tri-segmented genome includes a S (small), M (medium), and L (large) segment that code for nucleocapsid (N), glycoproteins G1 and G2, and L protein respectively. The S segment of the Andes virus contains 1876 nucleotides in total, while encoding a 547 nucleotide-long N protein. Upon comparison of S and M segments to other variants, the Andes virus was found to form a lineage with viruses such as ESQ H-1/96, CH H-1/96 Bayou, and Black Creek Canal viruses. When expressed, the M segment generates the glycoprotein precursor (GPC) which can be cleaved into the envelope Gn and Gc proteins. The L protein encoded by the L segment possesses enzymatic functions that are involved within transcription and replication.
In addition to these segments, the virion also contains RdRP which are all enclosed in an envelope. Unlike the other four genera in the family the hantavirion segments also contain a complementary 3'-terminal nucleotide sequence to the 5'-terminal sequence.These nucleotide sequences are AUCAUCAUCUG… at the 3′ end and UAGUAGUAUGC… at the 5′ end.
Entry and Replication Cycle
The Hantavirus replication takes place strictly in the cytoplasm of a host cell primarily targeting endothelial cells. During early infection, Andes virus can produce a week, innate immune response in the cell. The entry and uncoating of the virus begins when the virion attaches to cell receptors on the surface of the host cell, which then brings in the virus via endocytosis. By a process called pH-dependent fusion between the virion and the endosomal membrane, nucleocapsids enter the cytoplasm. The virus genome contains its own RNA-dependent RNA polymerase (RdRp) which directs both transcription and replication of the viral genome. Once the nucleocapsids are released, RdRp initiates transcription by binding to the encapsidated segments. While M segment mRNAs are translated by membrane-bound ribosomes, L and S segment mRNAs are translated by free ribosomes. Once transcribed, the mRNA is capped by L proteins via Cap snatching. These capped RNA fragments can then be transferred to L protein, to be further trimmed in length by the endonuclease and used by the RdRp to initiate viral mRNA synthesis. Replication is terminated when the plasma membrane begins to fuse with cytoplasmic vesicles and mature virions are released.
Signs and Symptoms
Initial signs of an Andes orthohantavirus infection can easily be mistaken for the flu. Signs and symptoms can appear as early as 4 days and up to 6 weeks after exposure. The only way to diagnose Andes orthohantavirus as the cause for these symptoms is by testing the patient's blood for Andes orthohantavirus genetic material or for corresponding antibodies of Andes orthohantavirus. Individuals are typically only infectious while they are showing symptoms such as having one or more of the following:
- Nausea and/or vomiting
- Muscle aches
- Shortness of breath
- Fluid in lungs
- Breathing in the virus aerosols; stirred up rodent feces or urine
- Direct contact with your eyes, nose, or mouth after touching infected rodent, its feces, urine, or nesting material
- Bite from infected rodent
- Although rare, through direct or close contact with an infected person
- Bodily fluids (blood, saliva, urine, or semen)
Associated Diseases, Prevention, and Treatment
Andes Hantavirus Pulmonary Syndrome (HPS)
Hantavirus pulmonary syndrome is an acute, severe, and sometimes fatal respiratory disease caused by an infection from the Andes orthohantavirus. Four to ten days after initial symptoms begin, respiratory symptoms indicating HPS can appear. Such symptoms include muscle aches, fatigue, shortness of breath, and fever. HPS symptoms can develop quickly, therefore, it is imperative to seek healthcare immediately. Early care is more beneficial to the patient as their is no vaccine or specific treatment for HPS. In extreme cases, infected individuals may be incubated and receive oxygen therapy.
Although hantavirus infections are prevalent in the United States, there currently are very few recorded cases of HPS due to infection from the Andes virus in the United States and the rest of North America; however, there have been several cases reported in Chile and Argentina.
Hantavirus Cardiopulmonary Syndrome (HCPS)
HCPS as a result of Andes orthohantavirus infection has a case fatality rate of about 25–35% in Argentina and 37% in Chile. ANDV, lineage ANDV-Sout, is the only hantavirus for which person-to-person transmission has been described; all other human hantavirus infections are transmitted exclusively from animals to humans. Several ANDV strains are co-circulating in Argentina (e.g. Bermejo, Lechiguanas, Maciel, Oran and Pergamino).[full citation needed] HCPS cases have also been reported in nearby Bolivia, Brazil, Paraguay and Uruguay, but only for Chile and Argentina can they be strictly associated with ANDV.
In Argentina and Chile, the long-tailed rice rat, Oligoryzomys longicaudatus, and other species of the genus Oligoryzomys, have been documented as the reservoir for ANDV. Another unique characteristic of ANDV is the availability of an animal model. ANDV causes lethal disease in the Syrian hamster (Mesocricetus auratus) that closely models the course of disease progression in humans, including a rapid progression from first symptoms to death, which is characterized by fluid in the pleural cavity and the histopathology of the lungs and spleen. Lethality of ANDV in hamsters is not true of all viruses causing HCPS; hamsters infected with Sin Nombre virus, for example, show no symptoms of disease. The availability of this model allows for the study of various drugs and other treatments that may affect the treatment of all HCPS-causing hantavirus infections.
Hemorrhagic Fever with Renal Syndrome/Failure (HFRS)
HFRS, also known as Korean hemorrhagic fever, epidemic hemorrhagic fever, and nephropathis epidemica, encompasses a group of clinically similar illnesses caused by species of hantaviruses such as Andes virus. A hantavirus-induced hemorrhagic fever incubation time is approximately two to four weeks in humans before symptoms develop. Their severity depends on the viral load within the infected individual.
When visiting geographical locations where Andes orthohantavirus has been documented, such as South America, people should avoid areas of high rodent populations where the virus is more likely to be found and transmitted quickly and easily from rodent to the next. Properly disinfecting living spaces and areas where rodents may have been present will kill the virus before it is able to be contracted. To prevent transmission from contact with infected humans, individuals, infected or not, should hand-wash frequently, abstain from kissing or sexual activity with one another, and avoid sharing spaces of close confinement for long periods of time.
There is no current treatment, cure, or vaccine available for illness caused by Andes virus. However, if patients seek medical attention quickly, early symptoms can be abated through intensive care or intubation, if necessary, for patients with severe breathing difficulties.
- Briese T, et al. (15 June 2015). "Implementation of non-Latinized binomial species names in the family Bunyaviridae" (PDF). International Committee on Taxonomy of Viruses (ICTV). Retrieved 8 March 2019.
- "Hantavirus | virus". Encyclopedia Britannica. Retrieved 2019-03-07.
- "ScienceDirect". www.sciencedirect.com. Retrieved 2019-03-07.
- "Fact Sheet about Andes Virus | Hantavirus | DHCPP | CDC". www.cdc.gov. 2019-02-20. Retrieved 2019-03-05.
- Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ (December 2005). "Person-to-person transmission of Andes virus". Emerging Infectious Diseases. 11 (12): 1848–53. doi:10.3201/eid1112.050501. PMC 3367635. PMID 16485469.
- Ermonval M, Baychelier F, Tordo N (August 2016). "What Do We Know about How Hantaviruses Interact with Their Different Hosts?". Viruses. 8 (8): 223. doi:10.3390/v8080223. PMC 4997585. PMID 27529272.
- "Andes virus". TheFreeDictionary.com. Retrieved 2019-03-07.
- Medina RA, Torres-Perez F, Galeno H, Navarrete M, Vial PA, Palma RE, et al. (March 2009). "Ecology, genetic diversity, and phylogeographic structure of andes virus in humans and rodents in Chile". Journal of Virology. 83 (6): 2446–59. doi:10.1128/JVI.01057-08. PMC 2648280. PMID 19116256.
- "Virology | Hantavirus | DHCPP | CDC". www.cdc.gov. 2019-02-26. Retrieved 2019-03-07.
- International Committee on Taxonomy of Viruses (ICTV) (2019). "Bunyaviridae". International Committee on Taxonomy of Viruses.
- Muyangwa M, Martynova EV, Khaiboullina SF, Morzunov SP, Rizvanov AA (November 2015). "Hantaviral Proteins: Structure, Functions, and Role in Hantavirus Infection". Frontiers in Microbiology. 6: 1326. doi:10.3389/fmicb.2015.01326. PMC 4661284. PMID 26640463.
- López N, Padula P, Rossi C, Miguel S, Edelstein A, Ramírez E, Franze-Fernández MT (July 1997). "Genetic characterization and phylogeny of Andes virus and variants from Argentina and Chile". Virus Research. 50 (1): 77–84. PMID 9255937.
- Heinemann P, Schmidt-Chanasit J, Günther S (June 2013). "The N terminus of Andes virus L protein suppresses mRNA and protein expression in mammalian cells". Journal of Virology. 87 (12): 6975–85. doi:10.1128/JVI.00043-13. PMID 23576516.
- Hepojoki J, Strandin T, Lankinen H, Vaheri A (August 2012). "Hantavirus structure--molecular interactions behind the scene". The Journal of General Virology. 93 (Pt 8): 1631–44. doi:10.1099/vir.0.042218-0. PMID 22622328.
- Wang Z, Mir MA (February 2015). "Andes virus nucleocapsid protein interrupts protein kinase R dimerization to counteract host interference in viral protein synthesis". Journal of Virology. 89 (3): 1628–39. doi:10.1128/JVI.02347-14. PMC 4300761. PMID 25410857.
- Muranyi W, Bahr U, Zeier M, van der Woude FJ (December 2005). "Hantavirus infection". Journal of the American Society of Nephrology. 16 (12): 3669–79. doi:10.1681/ASN.2005050561. PMID 16267154.
- "ViralZone page". viralzone.expasy.org. Retrieved 2019-03-07.
- "CDC - Hantavirus Pulmonary Syndrome (HPS) - Hantavirus". www.cdc.gov. 2019-02-22. Retrieved 2019-03-10.
- "Andes virus reported for the first time in US". Outbreak News Today. 2018-10-20. Retrieved 2019-03-13.
- Paula Padula. "Personal Communication". Buenos Aires.
- Government of Chile. "Ministry of Health, 2005".
- Padula; et al. "1998".[full citation needed]Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ (December 2005). "Person-to-person transmission of Andes virus". Emerging Infectious Diseases. 11 (12): 1848–53. doi:10.3201/eid1112.050501. PMC 3367635. PMID 16485469.
- Toro J, Vega JD, Khan AS, Mills JN, Padula P, Terry W, Yadón Z, Valderrama R, Ellis BA, Pavletic C, Cerda R, Zaki S, Shieh WJ, Meyer R, Tapia M, Mansilla C, Baro M, Vergara JA, Concha M, Calderon G, Enria D, Peters CJ, Ksiazek TG, et al. (October–December 1998). "An outbreak of hantavirus pulmonary syndrome, Chile, 1997". Emerging Infectious Diseases. 4 (4): 687–94. doi:10.3201/eid0404.980425. PMC 2640255. PMID 9866751.
- Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, Gonzalez Della Valle M, Mills JN, Peters CJ (October 1998). "Seroprevalence of antibodies to hantavirus in health care workers and other residents of southern Argentina". Clinical Infectious Diseases. 27 (4): 895–6. doi:10.1086/517161. PMID 9798052.
- Padula; et al. "2000, 2002".
- Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, Mills JN, Peters CJ, Segura EL (April–June 1997). "An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia". Emerging Infectious Diseases. 3 (2): 171–4. doi:10.3201/eid0302.970210. PMC 2627608. PMID 9204298.
- Levis S, Morzunov SP, Rowe JE, Enria D, Pini N, Calderon G, Sabattini M, St Jeor SC (March 1998). "Genetic diversity and epidemiology of hantaviruses in Argentina". The Journal of Infectious Diseases. 177 (3): 529–38. doi:10.1086/514221. PMID 9498428.
- Cantoni G, Padula P, Calderón G, Mills J, Herrero E, Sandoval P, Martinez V, Pini N, Larrieu E (October 2001). "Seasonal variation in prevalence of antibody to hantaviruses in rodents from southern Argentina". Tropical Medicine & International Health. 6 (10): 811–6. doi:10.1046/j.1365-3156.2001.00788.x. PMID 11679129.
- Hooper JW, Larsen T, Custer DM, Schmaljohn CS (October 2001). "A lethal disease model for hantavirus pulmonary syndrome". Virology. 289 (1): 6–14. doi:10.1006/viro.2001.1133. PMID 11601912.
- Canada, Public Health Agency of (2015-06-04). "Hantavirus pulmonary syndrome in Canada". aem. Retrieved 2019-03-13.
- "Andes Virus (Hantavirus) in Argentina - Watch - Level 1, Practice Usual Precautions - Travel Health Notices | Travelers' Health | CDC". wwwnc.cdc.gov. Retrieved 2019-03-07.
|Wikimedia Commons has media related to Hantavirus.|